News | January 14, 2015

Opsens Announces First use of FFR Products in Europe

OptoWire and OptoMonitor guide therapy in patients with coronary heart disease

FFR catheters, Cath lab, OptoWire, OptoMonitor

Image courtesy of Opsens

January 14, 2015 — Opsens Inc. announced the first use of its Fractional Flow Reserve (FFR) products in Europe by the founders of FFR, namely Bernard De Bruyne, M.D. at the Cardiovascular Center Aalst, Belgium and by professor Nico Pijls, at the Catharina Hospital, Eindhoven the Netherlands. The OptoWire and OptoMonitor are Opsens’ products for FFR measurements to optimize the diagnosis and guide the therapy in patients with coronary heart disease.

"The arrival of an optical FFR guidewire such as the OptoWire on the market is positive for interventional cardiologists who need to obtain reliable FFR measurements. It allowed me to appreciate its zero drift performance during all cases performed while also acknowledging the constant connection reliability as well as its support during percutaneous coronary intervention", said Bernard De Bruyne, M.D., from the Cardiovascular Center Aalst.

The OptoWire provides intra-coronary blood pressure measurements with optical pressure guidewire technologies. It is immune to adverse effects related to blood contact, and allows easy connectivity that leads to reliable FFR measurements in extended conditions of usage. The product is designed to provide cardiologists with a guidewire delivering optimized performances to navigate coronary arteries and reach blockages. Based on industry sources, the FFR market represented more than $250 million in U.S. sales in 2013 and is expected to reach $1 billion in the medium-term.  

For more information: www.opsens.com

 

Related Content

Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott While Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Overlay Init